Microphthalmia–dermal aplasia–sclerocornea syndrome
(Redirected from MIDAS syndrome)
Microphthalmia–dermal aplasia–sclerocornea syndrome is a rare genetic disorder characterized by a combination of eye abnormalities, skin abnormalities, and other physical and developmental problems.
Symptoms[edit | edit source]
The most common symptoms of Microphthalmia–dermal aplasia–sclerocornea syndrome include:
- Microphthalmia: This is a condition in which one or both eyes are abnormally small. In some cases, the eye may appear to be completely missing; however, even in these cases, some residual eye tissue is generally present. Such tissue may be visible only on ultrasound examination.
- Dermal aplasia: This is a condition characterized by the absence of certain layers of skin, resulting in areas of missing skin or abnormal skin growth.
- Sclerocornea: This is a condition in which the clear front surface of the eye (the cornea) becomes opaque and resembles the white part of the eye (the sclera).
Causes[edit | edit source]
Microphthalmia–dermal aplasia–sclerocornea syndrome is caused by mutations in the PAX6 gene. This gene provides instructions for making a protein that is involved in the formation of tissues and organs during embryonic development. Mutations in the PAX6 gene disrupt the normal development of the eyes and skin, leading to the characteristic features of this disorder.
Diagnosis[edit | edit source]
Diagnosis of Microphthalmia–dermal aplasia–sclerocornea syndrome is based on the presence of the characteristic symptoms. Genetic testing can confirm the diagnosis by identifying a mutation in the PAX6 gene.
Treatment[edit | edit source]
Treatment of Microphthalmia–dermal aplasia–sclerocornea syndrome is symptomatic and supportive. It may include surgery to correct eye abnormalities, skin grafts for areas of dermal aplasia, and other interventions as needed.
See also[edit | edit source]
Microphthalmia–dermal aplasia–sclerocornea syndrome Resources | |
---|---|
|
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD